U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

i

A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischemic stroke

Supporting Files
File Language:
English


Details

  • Journal Article:
    Stroke Vasc Neurol
  • Personal Author:
  • Description:
    Background

    Intravenous recombinant tissue plasminogen activator (IV rtPA) is recommended treatment for acute ischemic stroke patients, but the cost-effectiveness of IV rtPA within different time windows after the onset of acute ischemic stroke is not well reviewed.

    Aims

    To conduct a literature review of the cost-effectiveness studies about IV rtPA by treatment times.

    Summary of review

    A literature search was conducted using MEDLINE, EMBASE, CINAHL and Cochrane Library, with the key words acute ischemic stroke, tissue plasminogen activator, cost, economic benefit, saving, and incremental cost-effectiveness analysis. The review is limited to original research articles published during 1995-2016 in English-language peer-reviewed journals. We found 16 studies meeting our criteria for this review. Nine of them were cost-effectiveness studies of IV rtPA treatment within 0-3 hours after stroke onset, 2 studies within 3-4.5 hours, 3 studies within 0-4.5 hours, and 2 study within 0-6 hours. IV rtPA is a cost-saving or a cost-effectiveness strategy from most of the study results. Only one study showed incremental cost-effectiveness ratio of IV rtPA within one year was marginally above $50,000 per QALY threshold. IV rtPA within 0-3 hours after stroke led to cost savings for lifetime or 30 years, and IV rtPA within 3-4.5 hours after stroke increased costs but still was cost-effective.

    Conclusions

    The literature generally showed that intravenous IV rtPA was a dominant or a cost-effective strategy compared to traditional treatment for acute ischemic stroke patients without IV rtPA. The findings from the literature lacked generalizability because of limited data and various assumptions.
  • Subjects:
  • Source:
    Stroke Vasc Neurol. 2(2):73-83
  • Pubmed ID:
    28736623
  • Pubmed Central ID:
    PMC5516524
  • Document Type:
  • Funding:
  • Volume:
    2
  • Issue:
    2
  • Download URL:
  • File Type:
    Filetype[PDF - 801.54 KB]
  • Collection(s):
  • Main Document Checksum:
    urn:sha-512:e08177111934989e51e74601e3d67a65369fd761c39135578f363612dab9fc0ff35e68229659eefb0cbeb4673a0aeff2fbeb7f08a0ff3867279b821f12b669d6
File Language:
English
ON THIS PAGE
 Was this page helpful?
 Found an issue?
Send us an email at:
CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.